A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...
IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback